Inventor · disambiguated record
Aynur Hermann
Also filed as: HERMANN AYNUR
9 granted patents·12 pending applications·83 citations·filing 2016–2025
87Inventor score
Files withREGENERON PHARMA21
Top patents by PatentIndex Score
21 records- 0196US10358495B2Anti-LAG3 antibodies and uses thereofREGENERON PHARMA·Filed 2016·Granted Jul 23, 2019·47 cites·18 claims
- 0294US11548947B2Bispecific anti-PSMA X anti-CD28 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Jan 10, 2023·10 cites·17 claims
- 0393US11453721B2Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Sep 27, 2022·10 cites·30 claims
- 0492US11905332B2Antigen-binding molecules that bind CD38 and/or CD28, and uses thereofREGENERON PHARMA·Filed 2021·Granted Feb 20, 2024·3 cites·43 claims
- 0591US11396544B2Bispecific anti-CD28 × anti-CD22 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Jul 26, 2022·8 cites·10 claims
- 0688US11692032B2Anti-LAG3 antibodies and uses thereofREGENERON PHARMA·Filed 2019·Granted Jul 4, 2023·3 cites·28 claims
- 0785US10844137B2Anti-CTLA-4 antibodies and uses thereofREGENERON PHARMA·Filed 2018·Granted Nov 24, 2020·2 cites·20 claims
- 0883US2025122307A1Anti-CTLA-4 Antibodies and Uses ThereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 0977US2024166740A1Anti-lag3 antibodies and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1075US12441800B2Bispecific anti-PSMA x anti-CD28 antibodies and uses thereofREGENERON PHARMA·Filed 2022·Granted Oct 14, 2025·0 cites·14 claims
- 1171US2023174652A1Bispecific Anti-CD28 X Anti-CD22 Antibodies and Uses ThereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1270US12024570B2Anti-CTLA-4 antibodies and uses thereofREGENERON PHARMA·Filed 2020·Granted Jul 2, 2024·0 cites·21 claims
- 1368US2025223360A1Bispecific anti-cd28 x anti-cd22 antibodies and uses thereofREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 1468US2023279113A1Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses ThereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1567US2024277844A1Induced nk cells responsive to cd3/taa bispecific antibodiesREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1666US2022260577A1Biochemical assays for therapeutic proteinsREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1765US2024376229A1Interferon receptor antagonists and uses thereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 1862US2021341487A1Neutralizing antibody assay for therapeutic proteinsREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 1962US2023416396A1Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2056US2023374160A1Combination of antibodies for treating cancer with reduced cytokine release syndromeREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 2152US2025164501A1Biochemical assays for therapeutic proteinsREGENERON PHARMA·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Aynur Hermann files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →